Global Drug Discovery, Bayer Schering Pharma AG, Berlin, Germany.
J Nucl Med. 2010 Oct;51(10):1632-6. doi: 10.2967/jnumed.110.078899. Epub 2010 Sep 16.
The presence and localization of metastatic bone lesions is important for the staging of the disease and subsequent treatment decisions. Detecting tumor cells would have additional value over the current indirect bone scintigraphy method for detecting areas of elevated skeletal metabolic activity. d-(18)F-fluoromethyl tyrosine (d-(18)F-FMT) has recently shown good uptake and fast elimination, resulting in good tumor-to-background ratios. The potential of d-(18)F-FMT for imaging bone metastases has been investigated.
786-O/luciferase human renal adenocarcinoma cells were injected intracardially, resulting in the formation of bone metastases in mice. Small-animal PET was performed 51 and 65 d after tumor cell inoculation.
d-(18)F-FMT showed specific uptake in the bone metastases, giving excellent images with a little background in the pancreas. All imaged metastases were histologically confirmed. A bone scan with (18)F-fluoride showed elevated skeletal metabolic activity in the areas of osteolytic lesions.
d-(18)F-FMT is a useful PET tracer for the detection of bone metastases and should be evaluated in the clinical setting.
转移骨病变的存在和定位对于疾病的分期和随后的治疗决策很重要。与目前用于检测骨骼代谢活性升高区域的间接骨闪烁显像法相比，检测肿瘤细胞将具有额外的价值。d-(18)F-氟甲基酪氨酸（d-(18)F-FMT）最近显示出良好的摄取和快速消除，从而产生良好的肿瘤与背景比。已经研究了 d-(18)F-FMT 用于成像骨转移的潜力。
将 786-O/荧光素酶人肾腺癌细胞心内注射，导致小鼠形成骨转移。肿瘤细胞接种后 51 和 65 天进行小动物 PET。
d-(18)F-FMT 在骨转移部位显示出特异性摄取，在胰腺中有少许背景的情况下给出了极好的图像。所有成像的转移均经组织学证实。（18）F-氟化物骨扫描显示溶骨性病变区域骨骼代谢活性升高。
d-(18)F-FMT 是一种用于检测骨转移的有用 PET 示踪剂，应在临床环境中进行评估。
